Literature DB >> 3086473

Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo.

M Colucci, J A Paramo, D Collen.   

Abstract

The inhibition of one-chain and two-chain molecular forms of human tissue-type plasminogen activator (t-PA) by the fast-acting inhibitor of plasminogen activator (PA-inhibitor) present in plasma was studied in vitro and in vivo in rabbits. In vitro, both one-chain and two-chain forms of t-PA were neutralized very rapidly in rabbit plasma with high levels of PA-inhibitor. The rate constant of the interaction between two-chain t-PA and PA-inhibitor was estimated to be 3.10(7) L/mol/sec. The presence of CNBr-digested fibrinogen, which mimics the effect of fibrin on the activation of plasminogen by t-PA, did not influence the rate constant. Moreover, PA-inhibitor-rich plasma inhibited in a very similar way in vitro thrombolysis by one-chain or two-chain t-PA incorporated into the clot. Injection of one-chain or two-chain t-PA into rabbits with increased levels of PA-inhibitor, induced by endotoxin, resulted in very rapid inhibition of t-PA activity. Within 30 seconds after injection, no residual free t-PA could be demonstrated. Gel filtration analysis showed that the disappearance of t-PA activity was associated with the generation of t-PA-PA-inhibitor complex with an apparent Mr of 100,000. This enzyme-inhibitor complex, like free t-PA, was cleared from the circulation with a half-life of approximately 2 minutes, mainly via the liver. It is concluded that PA-inhibitor neutralizes one-chain and two-chain molecular forms of t-PA in plasma at very similar rates, both in vitro and in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086473

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

1.  Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions.

Authors:  J Chmielewska; M Rånby; B Wiman
Journal:  Biochem J       Date:  1988-04-15       Impact factor: 3.857

2.  Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.

Authors:  R R Schleef; D L Higgins; E Pillemer; L J Levitt
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

Review 3.  Prognostic significance of proteolytic enzymes in human brain tumors.

Authors:  A K Bindal; M Hammoud; W M Shi; S Z Wu; R Sawaya; J S Rao
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor on the surface of activated endothelial cells.

Authors:  R R Schleef; D J Loskutoff; T J Podor
Journal:  J Cell Biol       Date:  1991-06       Impact factor: 10.539

5.  The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.

Authors:  R R Schleef; T J Podor; E Dunne; J Mimuro; D J Loskutoff
Journal:  J Cell Biol       Date:  1990-01       Impact factor: 10.539

6.  Neuroserpin Differentiates Between Forms of Tissue Type Plasminogen Activator via pH Dependent Deacylation.

Authors:  Karen-Sue B Carlson; Lan Nguyen; Kat Schwartz; Daniel A Lawrence; Bradford S Schwartz
Journal:  Front Cell Neurosci       Date:  2016-06-15       Impact factor: 5.505

Review 7.  Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation.

Authors:  Yunn-Hwa Ma; Chih-Hsin Liu; Yueh Liang; Jyh-Ping Chen; Tony Wu
Journal:  Molecules       Date:  2019-09-19       Impact factor: 4.411

8.  Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke.

Authors:  Hongyin Ma; Zhenmin Jiang; Jiayun Xu; Junqiu Liu; Zhen-Ni Guo
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.